8-KLeadership Changes

DEXCOM INC 8-K Report, Executive Changes (Aug 31, 2022)

Filed August 31, 2022For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced a significant internal promotion via an 8-K filing on August 31, 2022, detailing an event on August 25, 2022. Jacob S. Leach has been appointed as the new Executive Vice President, Chief Operating Officer. Mr. Leach is a long-tenured executive within DexCom, having previously served as Executive Vice President, Chief Technology Officer since 2018, and holding various research and development roles since 2004. This promotion reflects a strategic move to leverage his extensive experience within the company, particularly his deep background in glucose sensing systems development, into a broader operational leadership role. In connection with his new position, Mr. Leach's annual base salary has been increased to $600,300. He will also be eligible for an annual cash performance bonus, with a target set at 75% of his base salary. The determination of the actual bonus amount will be at the discretion of the Board's compensation committee. This appointment and compensation adjustment indicate a commitment to internal talent development and a structured approach to executive leadership within DexCom.

Key Highlights

  • 1Jacob S. Leach promoted to Executive Vice President, Chief Operating Officer, effective August 25, 2022.
  • 2Mr. Leach has a strong internal track record, previously serving as EVP, Chief Technology Officer since 2018 and in R&D roles since 2004.
  • 3The promotion signifies leveraging deep technical and development expertise into an operational leadership capacity.
  • 4New annual base salary for Mr. Leach is set at $600,300.
  • 5Mr. Leach is eligible for an annual cash performance bonus with a target of 75% of his base salary.
  • 6Bonus payout is subject to determination by the Board's compensation committee.
  • 7No undisclosed arrangements or family relationships with other officers/directors were noted for Mr. Leach.

Frequently Asked Questions

Jacob S. Leach has been promoted to Executive Vice President, Chief Operating Officer, effective August 25, 2022.

Mr. Leach has extensive experience with DexCom, having served as Executive Vice President, Chief Technology Officer since October 2018. Prior to that, he held various leadership roles in Research and Development from 2004 onwards, and also has prior experience in glucose sensing systems development at MiniMed and Medtronic Diabetes.

His annual base salary has been increased to $600,300. He is also eligible for an annual cash performance bonus with a target of 75% of his base salary, with the final amount determined by the compensation committee.

The filing states there are no undisclosed arrangements with other individuals that led to his selection, no family relationships with other executives or directors, and no material indirect or direct interest in any reportable transactions.